Review the role of low-density lipoprotein cholesterol (LDLc) in the pathogenesis of cardiovascular disease and the impact of LDLc lowering for CVD event reduction. |
|
|
|
|
|
|
Discuss the latest guidelines and expert consensus recommendations on LDLc thresholds for primary prevention and secondary prevention of coronary artery disease. |
|
|
|
|
|
|
Discuss current LDLc lowering pharmacologic therapies, including statin and non-statin options and the role for combination therapy. |
|
|
|
|
|
|